Relation between the empiric initial therapy of S.pneumoniae community-acquired pneumonia (SP-CAP) and mortality in thirty days of outcome. On behalf of Pneumococcal Pneumonia Cooperative Study Group, Grupo TIR, SEPAR

J. Aspa, O. Rajas, F. Rodriguez de Castro, R. Zalacain, R. De Celis, J. Blanquer, A. Torres (Madrid, Spain)

Source: Annual Congress 2003 - New aspects of community acquired pneumonia
Session: New aspects of community acquired pneumonia
Session type: Oral Presentation
Number: 141
Disease area: Respiratory infections

Congress or journal article abstractSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Aspa, O. Rajas, F. Rodriguez de Castro, R. Zalacain, R. De Celis, J. Blanquer, A. Torres (Madrid, Spain). Relation between the empiric initial therapy of S.pneumoniae community-acquired pneumonia (SP-CAP) and mortality in thirty days of outcome. On behalf of Pneumococcal Pneumonia Cooperative Study Group, Grupo TIR, SEPAR. Eur Respir J 2003; 22: Suppl. 45, 141

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Shortening duration of antibiotic therapy according to clinical stability in patients with community-acquired pneumonia (CAP)
Source: International Congress 2014 – Respiratory infections: inflammation and treatment
Year: 2014


Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP)
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013


Nursing and healthcare-associated pneumonia requiring hospital admission: Microbiology and clinical outcomes
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014


Antimicrobial therapy of community-acquired pneumonia (CAP) at an out-patient stage in the Samara region during the 5-year period
Source: Annual Congress 2013 –Manifestations, scores and prognosis of community-acquired pneumonia
Year: 2013

Clinical judgement on top of CURB65-score in predicting 30 days clinical outcome in patients with community acquired pneumonia (CAP) admitted to the hospital
Source: International Congress 2014 – Pathogenesis and mechanisms of respiratory infections
Year: 2014

Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study
Source: Eur Respir J 2006; 28: Suppl. 50, 349s
Year: 2006

Comparative evaluation of timing of antibiotic intravenous-to-oral switch in pneumonia
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014


LATE-BREAKING ABSTRACT: Pneumococcal serotypes causing community-acquired pneumonia (CAP) among hospitalized adults in Spain using a new urinary antigen detection (UAD) test. The CAPA study
Source: International Congress 2014 – New technologies and biomarkers in lung disease
Year: 2014


Risk of hospitalization due to pneumococcal pneumonia in adults in Spain. The CORIENNE study
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015


Does previous warfarin treatment effect complications and outcome in hospitalised patients with community-acquired pneumonia?
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014


Immunoglobulin levels and severity of community-acquired pneumonia (CAP)
Source: International Congress 2014 – Pathogenesis and mechanisms of respiratory infections
Year: 2014


Health care-associated pneumonia and community-acquired pneumonia: A single-center experience
Source: International Congress 2015 – CAP: prognostic factors in frail patients
Year: 2015

Clinical impact of a prediction score for drug-resistance in community-onset pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016


Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015

Prior antibiotics and outcomes in patients hospitalized with pneumonia
Source: International Congress 2015 – CAP: prognostic factors in frail patients
Year: 2015

Use of pneumonia severity index in Spain to decide hospitalization among patients with community-acquired pneumonia (CAP). (Nacar Study)
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005

Modification of empirical antibiotic therapy in community acquired pneumonia
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014


Microbiological vs non-microbiological confirmed nnventilator ICU-acquired pneumonia
Source: International Congress 2016 – Severe respiratory infections in the intensive care unit and pleural and fungal infections
Year: 2016


Simplifying IDSA/ATS pneumonia guidelines
Source: Annual Congress 2013 –Viral infections: what is new?
Year: 2013


Microbiology and outcomes in patients with pneumonia in an English Hospital
Source: International Congress 2014 – Clinical problems in acute and chronic lung diseases
Year: 2014